(1.38%) 5 134.15 points
(1.30%) 38 723 points
(2.17%) 16 185 points
(-1.09%) $78.09
(5.85%) $2.15
(-0.06%) $2 308.20
(-0.66%) $26.65
(0.14%) $963.95
(-0.37%) $0.929
(-1.17%) $10.86
(-0.14%) $0.797
(0.37%) $91.47
1.45% $ 951.21
@ $951.18
Emitido: 3 may 2024 @ 14:01
Retorno: 0.00%
Señal anterior: may 2 - 14:27
Señal anterior:
Retorno: 1.79 %
Live Chart Being Loaded With Signals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion...
Stats | |
---|---|
Volumen de hoy | 223 436 |
Volumen promedio | 472 833 |
Capitalización de mercado | 103.08B |
EPS | $0 ( 2024-05-02 ) |
Próxima fecha de ganancias | ( $10.09 ) 2024-06-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.36 |
ATR14 | $21.59 (2.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Yancopoulos George | Buy | 18 148 | Common Stock |
2024-04-29 | Yancopoulos George | Sell | 36 296 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 2 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 2 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 9 | Common Stock |
INSIDER POWER |
---|
-30.01 |
Last 100 transactions |
Buy: 249 600 | Sell: 463 125 |
Volumen Correlación
Regeneron Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
CFBK | 0.904 |
NNBR | 0.894 |
VTRS | 0.875 |
PBPB | 0.874 |
GANX | 0.866 |
FTXH | 0.862 |
IMTX | 0.862 |
BKCC | 0.859 |
FXCO | 0.853 |
ARDX | 0.848 |
10 Correlaciones Más Negativas | |
---|---|
OSMT | -0.879 |
SVOK | -0.85 |
OPK | -0.847 |
SEV | -0.833 |
GHVI | -0.83 |
RAAC | -0.83 |
BFRI | -0.83 |
GOODM | -0.828 |
MLVF | -0.827 |
AMTI | -0.807 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Regeneron Pharmaceuticals Correlación - Moneda/Commodity
Regeneron Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $13.12B |
Beneficio Bruto: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2023 |
Ingresos: | $13.12B |
Beneficio Bruto: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2022 |
Ingresos: | $12.17B |
Beneficio Bruto: | $10.61B (87.18 %) |
EPS: | $40.51 |
FY | 2021 |
Ingresos: | $16.07B |
Beneficio Bruto: | $13.63B (84.83 %) |
EPS: | $76.40 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
REGN | Q4 | 2023 | Financial Report for REGN - Q4 2023 |
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico